methyl 6-(methylamino)hexanoate hydrochloride | 154024-74-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 6-(methylamino)hexanoate hydrochloride
• 英文别名: methyl 6-methylamino-caproate hydrochloride；Methyl 6-(methylamino)hexanoate;hydrochloride
• CAS: 154024-74-5
• 化学式: C₈H₁₇NO₂*ClH
• 分子量: 195.689
• InChiKey: VPEZGEGIQMQXPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.36
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 6-(methylamino)hexanoate hydrochloride 、 (+)生物素-N-琥珀酰亚胺基酯 生成 methyl N-methyl-caproylamido-biotin
  参考文献：
  名称：

  THREE-STEP PRETARGETING METHODS AND COMPOUNDS

  摘要：

  涉及预定位递送诊断和治疗药物的方法、化合物、组合物和试剂盒已被披露。具体而言，描述了三步预定位方法。

  公开号：

  US20020015705A1
• 作为产物：
  描述：

  N-甲基己内酰胺 在 盐酸 、 氯化亚砜 作用下， 以 水 为溶剂， 反应 49.0h， 生成 methyl 6-(methylamino)hexanoate hydrochloride
  参考文献：
  名称：

  附在荧光团上的通用光激活标签使其可用于单分子成像

  摘要：

  我们开发了一种通过在荧光分子上引入通用标签 SO 来构建可光激活探针的通用策略。该策略适用于大多数具有各种骨架结构的商业荧光团。我们成功地将这些光敏探针应用于活细胞中的延时超分辨率跟踪和固定神经元微管的超分辨率成像。

  DOI：

  10.1002/anie.202211767

文献信息

• Non-steroidal compounds for steroid receptors and uses relating thereto
  申请人：NeoRx Corporation

  公开号：US06534037B1

  公开（公告）日：2003-03-18

  Steroid receptor analogs having good binding affinity for steroid receptors and “binding arms” for chelation to metal species such as radionuclides are prepared with all carbon backbones. The analogs very closely approximate the geometries present in natural steroids which are important for effective binding to receptor sites. In addition, metal species binding arms are strategically incorporated into the analog structure in a manner that does not disrupt the analog's receptor binding efficacy. Furthermore, the metal species binding arms may be designed to chelate one or more radionuclides, including radionuclides effective in diagnostic or therapeutic applications. With incorporation of an appropriate steroid receptor binding group, these metal species-bound analogs may be used, for example, to bind androgen receptor sites in the diagnosis or treatment of prostate cancer, or estrogen receptor sites in the diagnosis or treatment of breast and ovarian cancers.

  类固醇受体类似物具有良好的结合亲和力，用于与金属物种（如放射性核素）螯合的“结合臂”是通过全碳骨架制备的。这些类似物非常接近天然类固醇中存在的几何结构，这对于有效结合受体位点至关重要。此外，金属物种结合臂被策略性地并入类似物结构中，以一种不会破坏类似物受体结合效力的方式。此外，金属物种结合臂可以设计成螯合一个或多个放射性核素，包括在诊断或治疗应用中有效的放射性核素。通过合适的类固醇受体结合基团的引入，这些金属物种结合的类似物可以用于例如结合雄激素受体位点以诊断或治疗前列腺癌，或结合雌激素受体位点以诊断或治疗乳腺癌和卵巢癌。
• Small molecular weight ligand-hexose containing clearing agents
  申请人：NeoRx Corporation

  公开号：US06075010A1

  公开（公告）日：2000-06-13

  Small molecule weight clearing agents containing ligands such as biotin or biotin analogs and hexose residue, in particular galactose or N-acetyl galactosamine residues are taught. These clearing agents effectively clear anti-ligand containing conjugates in vivo via hepatocyte receptor mediated clearance mechanisms.

  含有生物素或生物素类似物和六碳糖残基，特别是半乳糖或N-乙酰半乳糖氨基残基的小分子重量清除剂被教授。这些清除剂通过肝细胞受体介导的清除机制有效地清除体内含有抗配体的结合物。
• Carbamic acid compounds comprising an amide linkage as hdac inhibitors
  申请人：——

  公开号：US20040092598A1

  公开（公告）日：2004-05-13

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

  这项发明涉及抑制HDAC活性的某些活性碳酸酰胺化合物，其化学式为（1），其中：A是芳基；Q1是至少有2个碳原子骨架的芳基前导基团；J是选择自以下的酰胺键：—NR1C(═O)—和—C(═O)NR1—；R1是酰胺取代基；Q2是酸前导基团；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这种化合物的药物组合物，以及在体外和体内使用这种化合物和组合物来抑制HDAC，例如，抑制增殖性疾病，如癌症和牛皮癣。
• Pretargeting methods and compounds
  申请人：NeoRx Corporation

  公开号：US05541287A1

  公开（公告）日：1996-07-30

  Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Articles of manufacture useful in pretargeting methods are also discussed.

  涉及预定位传递诊断和治疗药剂的方法、化合物、组合物和试剂盒已被披露。具体来说，描述了生物素的放射金属标记方法，以及相关化合物。还讨论了在预定位方法中有用的制品。
• Three-step pretargeting methods using improved biotin-active agent
  申请人：Neorx Corporation

  公开号：US05578287A1

  公开（公告）日：1996-11-26

  Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.

  涉及预定位递送诊断和治疗药物的方法、化合物、组合物和试剂盒已被披露。具体来说，描述了三步预定位方法。